Clinical Trials on Dyslipidemias in Australia

Total 110 results

Amgen

Completed

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody (FLOREY)

Primary Hyperlipidemia and Mixed Dyslipidemia

Australia
Chong Kun Dang Pharmaceutical

Completed

To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors

Dyslipidemias

Australia
Arrowhead Pharmaceuticals

Completed

Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)

Mixed Dyslipidemia

United States, Australia, Poland, New Zealand, Canada, Hungary
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Orient Pharma Co., Ltd.

Completed

Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Primary Hypercholesterolemia | Mixed Dyslipidemias

Taiwan, Australia, New Zealand
Silence Therapeutics plc
Medpace, Inc.

Completed

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

Dyslipidemias | Hyperlipidemias | Elevated Lp(a)

United States, Australia, United Kingdom, Netherlands
AstraZeneca

Completed

A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome

Metabolic Syndrome | Dyslipidemia

Australia
The University of Western Australia

Completed

Regulation of Lipoprotein Metabolism in Obese Men

Obesity | Insulin Resistance | Dyslipidemia

Australia
AstraZeneca

Completed

Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)

Metabolic Syndrome | Dyslipidemia

Australia
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2)

Mixed Dyslipidemia

United States, Australia, Canada, New Zealand
The University of Western Australia

Completed

Effect of Abdominal Obesity on Lipoprotein Metabolism

Obesity | Insulin Resistance | Dyslipidemia

Australia
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-APOC3 in Adults With Dyslipidemia

Dyslipidemias

United States, Australia, Canada, Poland, Netherlands, New Zealand, Hungary
Resverlogix Corp
South Australian Health and Medical Research Institute

Terminated

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

Coronary Artery Disease | Dyslipidemia

Australia
Bristol-Myers Squibb

Completed

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, United States, Australia
Bristol-Myers Squibb

Completed

Safety Study of BMS-816336 in Healthy Male Subjects

Dyslipidemia | Diabetes Mellitus, Non-Insulin-Dependent

Australia
Novartis Pharmaceuticals

Recruiting

Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD (VICTORION REAL)

Mixed Dyslipidemia | Primary Hypercholesterolemia

Switzerland, Saudi Arabia, United Arab Emirates, United Kingdom, Austria, Israel, China, Malaysia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)

Hypercholesterolemia | Mixed Dyslipidemia

Austria, United Kingdom, Italy, Germany, Belgium
Sanofi

Completed

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients (ADAGIO-lipids)

Obesity | Dyslipidemia

United States, Canada, Brazil, Australia, Italy, Sweden, Malaysia, Singapore, Taiwan, Mexico, Denmark, Korea, Republic of, Hong Kong, South Africa
Amgen

Completed

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia (OSLER-2)

Hyperlipidemia and Mixed Dyslipidemia

United States, Canada, Denmark, France, Italy, Belgium, Czechia, Taiwan, Japan, Switzerland, Germany, United Kingdom, Korea, Republic of, Hong Kong, Netherlands, New Zealand, South Africa, Australia, Spain, Austria, Hungary, Russian... and more
Amgen

Completed

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)

Dyslipidemia

United States, Belgium, Denmark, Finland, France, Italy, Spain, Hungary, Poland, Germany, Czechia, Turkey, United Kingdom, Malaysia, Australia, Hong Kong, New Zealand, Canada, South Africa, Greece, Portugal, Netherlands, Russian Federation and more
Arrowhead Pharmaceuticals

Completed

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

Dyslipidemias | Hypertriglyceridemia | Familial Hypercholesterolemia

Australia, New Zealand
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Dyslipidemia

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Czechia, Hungary, Taiwan, Colombia, Poland, Russian Federation, Switzerland, Korea, Republic of, Mexico, ... and more
Sanofi

Completed

Obese Patients With Untreated Dyslipidemias (RIO-Lipids)

Obesity | Dyslipidemia

United States, Canada, Australia, Italy, Spain, Sweden, Switzerland, Finland
Pfizer

Completed

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-HR)

Hyperlipidemia

Korea, Republic of, United States, Australia, Germany, Poland, Canada, Italy, Hong Kong, Czech Republic
Swisse Wellness Pty Ltd
Commonwealth Scientific & Industrial Research Organisation; BIONAP SRL

Completed

Investigating Effects of a Novel Nutraceutical on Hypercholesterolaemia in Australian Adults (CLoNE)

Hypercholesterolemia

Australia
HighTide Biopharma Pty Ltd

Completed

A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia

Hypercholesterolemia

Australia
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI); St Vincent's Hospital, Sydney and other collaborators

Completed

Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects

Glucose Metabolism Disorders | Metabolic Diseases | HIV Infections | Cardiovascular Disease | Dyslipidemias | Lipodystrophy

Australia
Medical University of Vienna

Unknown

Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) (NASCIT)

Atherosclerosis | Dyslipidemia

Austria
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Dyslipidemia

United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Turkey, United Arab Emirates, United Kingdom
University of South Australia
American Egg Board

Completed

Independent Effects of High-cholesterol (High-egg) and High-saturated Fat Diets on LDL-cholesterol

Hypercholesterolemia | Hyperlipidemias | Diet, Healthy | Physical Inactivity

Australia
Marea Therapeutics

Recruiting

Study of MAR001 in Adults With Metabolic Dysfunction

Hypertriglyceridemia

Australia
LipimetiX Development, LLC

Completed

Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

Hypercholesterolemia | Hyperlipoproteinemia Type II

Australia
The George Institute
Pfizer; Royal Prince Alfred Hospital, Sydney, Australia; Lipid and Cardiovascular... and other collaborators

Completed

Study to Assess if Internet-Based Tailored Advice Could Modify Behaviour to Improve Health

Hypercholesterolemia

Australia
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia. (JEWEL II)

Hypertension | Hyperlipidemia

Greece, Austria, Finland, Italy, Hungary, Belgium, Spain, Ireland, Portugal, Slovenia, Switzerland
The University of Western Australia
National Health and Medical Research Council, Australia

Unknown

Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils (FIFH)

Familial Hypercholesterolaemia | Hypertriglyceridaemia

Australia
Affiris AG
Medical University of Vienna

Completed

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects (AFF012)

Hypercholesterolemia

Austria
Medical University of Graz

Completed

Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk

Hypercholesterolemia

Austria
Vaxxinity, Inc.
Novotech (Australia) Pty Limited

Active, not recruiting

A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants

Hypercholesterolemia

Australia
Moritz Oberndorfer
Merck Gesellschaft mbH, Austria

Completed

Lipid Profile and Diabetes Mellitus in People With HIV

HIV Infections | Diabetes Mellitus | Dyslipidemias | Cardiovascular Risk Factor

Austria
Ikaria Bioscience Pty Ltd

Recruiting

Adult Subjects With Elevated Low-Density Lipoprotein-Cholesterol to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects

To Reduce the LDL-C Level in Hypercholesteremia Adult Patients | Combination for Subgroup High LDL-c Patients With Other Comorbidities

Australia
Monash University
National Health and Medical Research Council, Australia

Active, not recruiting

Statins in Reducing Events in the Elderly (STAREE) Heart Sub-study (STAREE-HEART)

Heart Failure | Atrial Fibrillation | Hypercholesterolemia | Healthy Ageing

Australia
Western Sydney Local Health District

Completed

Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome (MVENT)

Metabolic Syndrome | Hypercholesterolemia

Australia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI)

Cardiovascular Diseases | Dyslipidemia | Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Finland, Netherlands, Spain, Belgium, Sweden, Austria, United Kingdom, Switzerland, Denmark, France, Germany, Portugal, Italy, Ireland
Mylan Inc.
Mylan Österreich GmbH; Mylan Germany GmbH; Mylan Healthcare Sp. z o.o.

Completed

Observation of the Effects of Guideline-driven Lifestyle Interventions, Including Use of a Red-yeast Based Nutraceutical

Hypercholesterolemia

Germany, Austria
Unilever R&D
Commonwealth Scientific and Industrial Research Organisation, Australia

Completed

The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus

Vascular Diseases | Diabetes Mellitus | Hypercholesterolemia

Australia
Daiichi Sankyo, Inc.

Completed

Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol

Hypercholesterolemia

United States, South Africa, Israel, Netherlands, Canada, Norway, Austria, Australia
Hoffmann-La Roche

Completed

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)

China, United States, Spain, Netherlands, Canada, France, Mexico, Poland, Hungary, Australia, Denmark, United Kingdom, Czech Republic
Glycemic Index Laboratories, Inc
University of Toronto; University of Guelph; University of Sydney; Agriculture... and other collaborators

Completed

Effect of the Molecular Weight of Oat β-glucan on Its Ability to Lower Serum Cholesterol (Bluebird)

Hypercholesterolemia

Canada, Australia, United Kingdom
Amgen

Completed

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection

Canada, France, United States, Belgium, Italy, Spain, Switzerland, United Kingdom, South Africa, Portugal, Australia, Greece, Brazil, Romania, Poland
Arrowhead Pharmaceuticals

Completed

Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

Hypertriglyceridemia | Familial Chylomicronemia

Australia, Canada, New Zealand

Clinical Trials on Dyslipidemias in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations